A comparison of two controlled-release delivery systems for the delivery of amiloride to control angiogenesis.
The diuretic amiloride has been reported to inhibit both Na+-H+ antiport and the urokinase-type plasminogen activator. As a consequence of these inhibitions, neovascularization may also be inhibited. We hypothesized that if amiloride could be effectively delivered in a site-specific manner, a system might be developed that could inhibit localized angiogenesis. In order to evaluate this possibility we conducted a study that compared two different controlled-release systems into which amiloride had been incorporated. The effectiveness of amiloride release from each delivery system was determined by quantitating angiogenic patterns in a chick chorioallantoic membrane (CAM) system using a fractal analysis software program. The two delivery systems compared were sucrose acetate isobutyrate (SAIB) and calcium alginate. Initial HPLC laboratory tests confirmed that amiloride could be released from both SAIB and calcium alginate in vitro in a sustained manner for 72 h. The CAM studies confirmed that neither SAIB nor calcium alginate alone promoted or inhibited angiogenesis when compared to nontreated controls. The release of amiloride from each delivery vehicle resulted in a significant (P < 0.05) inhibition of angiogenesis following both 24 and 48 h of release compared to controls. There was no difference in inhibition of angiogenesis, however, when comparing SAIB + amiloride treated CAMs with calcium alginate + amiloride treated CAMs. These data suggest that both SAIB and calcium alginate may be useful delivery vehicles for the localized application of amiloride to control angiogenesis. Such a system could potentially control tumor angiogenesis without systemic effects.
Knoll
A
A
The Falor Center for Vascular Studies, Akron City Hospital, Summa Health System, 525 E. Market Street, Akron, Ohio 44309, USA.
Schmidt
S
S
Chapman
M
M
Wiley
D
D
Bulgrin
J
J
Blank
J
J
Kirchner
L
L
D000464:Alginates / Q000008:administration & dosage / Q000494:pharmacology; D000482:Allantois / Q000098:blood supply; D000584:Amiloride / Q000008:administration & dosage* / Q000494:pharmacology; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000494:pharmacology; D002642:Chick Embryo; D002823:Chorion / Q000098:blood supply; D002851:Chromatography, High Pressure Liquid; D003692:Delayed-Action Preparations; D004791:Enzyme Inhibitors / Q000008:administration & dosage* / Q000494:pharmacology; D017709:Fractals; D020723:Glucuronic Acid; D006603:Hexuronic Acids; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors*; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D014677:Pharmaceutical Vehicles; D017923:Sodium-Hydrogen Exchangers / Q000037:antagonists & inhibitors; D013395:Sucrose / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology; D014568:Urokinase-Type Plasminogen Activator / Q000037:antagonists & inhibitors*
D000464:Alginates; D000970:Antineoplastic Agents; D003692:Delayed-Action Preparations; D004791:Enzyme Inhibitors; D006603:Hexuronic Acids; D009363:Neoplasm Proteins; D014677:Pharmaceutical Vehicles; D017923:Sodium-Hydrogen Exchangers; D013395:Sucrose; D000584:Amiloride; D020723:Glucuronic Acid; D014568:Urokinase-Type Plasminogen Activator; C002885:sucrose acetate isobutyrate